A number of global stocks that trade in the U.S. have the potential to more than double over the next 12 months, according to average analyst price targets. CNBC Pro screened for U.S.-traded stocks of overseas-headquartered firms covered by 10 or more analysts. The table below lists 11 stocks that analysts give over 100% upside potential in their local currency over the next 12 months. Investors should note that these stocks are exposed to foreign exchange fluctuations. Patriot Battery Metals Canada’s Patriot Battery Metals has the biggest consensus upside potential — 259% over the next 12 months — of the stocks screened using FactSet data, although analysts view the hard-rock lithium exploration company as a risky bet. Lithium, currently produced from hard rock or brine deposits, has become a sought-after metal in the electric vehicle industry. Although the company has a primary listing on the Toronto stock exchange, the stock is also traded on U.S. stock exchanges . PMETF 1Y line The company recently unveiled its plans for its Shaakichiuwaanaan lithium project in James Bay, Québec. “In our view, the [preliminary economic assessment] shows attractive project economics and reinforces the potential for PMET to become an important global hard rock lithium player,” said Desjardins analysts led by Frederic Tremblay in a note to clients on Aug. 22. The investment bank has a “speculative buy” rating and a price target of 16.50 Canadian dollars ($12.16) on the stock. Similarly, Canaccord Genuity analysts Katie Lachapelle and Meaghan Charlebois have a “speculative buy” rating and a price target of 13 Canadian dollars on the stock. Valneva France-based Valneva has the second-biggest consensus upside potential on the list, at 213%. It is one of a handful of remaining independent vaccine companies and has already successfully developed two in-house vaccines. It is also leading the development of a Lyme disease vaccine with pharmaceutical giant Pfizer . Analysts say that the company stands to deliver strong sales from its approved vaccines, with long-term growth from royalties possible if the launch of the Lyme disease vaccine is successful. “Valneva’s latest read-out from its [phase-2 trial] of its Lyme disease vaccine candidate (VLA15) continues to highlight the vaccine’s potential, demonstrating a potent immune response against Lyme as part of a booster regimen,” said Stifel analyst Christian Glennie in a note to clients on Sept. 3. “As a reminder, Pfizer and Valneva’s [phase-3] clinical trial (VALOR) is ongoing. The primary vaccination series was completed in July 2024 and the trial is expected to be completed by the end of 2025.” Stifel’s price target of 9 euros ($9.94) a share indicates a 201% upside potential. While Valneva is listed on the Paris stock exchange, it also trades on U.S. exchanges . VALN 1Y line Similarly, analysts at Guggenheim Securities are bullish on the stock over the next 12 months. “We forecast VALN operating margins expanding to a mid-40% range over time (given growing contribution of Lyme royalties) and assume a 21% tax rate after expiration of [Net Operating Loss],” said Guggenheim analyst led by Evan Wang in a note to clients on Aug. 14. Investors also cautioned that the stock carries some specific risks, however. “While we view VALN’s late-stage clinical programs as substantially de-risked, there remains some clinical, manufacturing, and commercialization risk before and after licensure,” the analysts added.
